Apollo And ReShape Swap Bariatric Devices
Executive Summary
Apollo Endosurgery sold its surgical product line, including the Lap-Band adjustable gastric banding system and other accessories for laparoscopic bariatric surgery, to ReShape Lifesciences for $17m plus other considerations, including the ReShape endoscopic balloon, the companies announced Dec. 18. The deal will allow Apollo to focus on endo-bariatric procedures while it gives ReShape an instant revenue stream and another product to sell to surgeons, its core customers.
You may also be interested in...
Gastric Balloon Labeling Updated After Patient Deaths
US FDA has approved updated labeling for Orbera Intragastric Balloon System and the ReShape Integrated Dual Balloon System in the wake of five more patient deaths.
EnteroMedics Inflates Neuromod-Obesity Offering With ReShape Balloon
The deal, worth $61m in cash and stock, will add ReShape's Dual Weight Loss Balloon to EnteroMedics' vBloc neurometabolic therapy and Gastric Vest System for the treatment of obesity.
Allergan trims off fat-busting portfolio to Apollo
Allergan has found a buyer for its underperforming obesity device business, nearly a year after putting it on the block. Austin, Texas-based Apollo EndoSurgery has definitively agreed to acquire the division, responsible for manufacturing and selling Allergan’s Lap-Band adjustable gastric band system and the Orbera intragastric balloon system, for up to $110m. The final consideration comprises a $75m upfront cash payment, a $15m stake in Allergan, and up to $20m in milestone payments linked to regulatory and sales targets.